As of May 19
| +0.0017 / +0.32%|
The 3 analysts offering 12-month price forecasts for Mateon Therapeutics Inc have a median target of 2.00, with a high estimate of 2.00 and a low estimate of 2.00. The median estimate represents a +276.15% increase from the last price of 0.53.
The current consensus among 3 polled investment analysts is to Buy stock in Mateon Therapeutics Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.